Cell culture-based influenza vaccines: A necessary and indispensable investment for the future

References

• Rappuoli R, Pizza M, del Guidice G, de Gregorio E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci U SA 2014; 111:12288-93; PMID:25136130; http://dx.doi.org/10.1073/pnas.1402981111
   PubMed Web of Science ®Google Scholar
• Morens DM, Taubenberger JK, Folkers GK, Fauci AS. Pandemic influenza's 500th anniversary. Clin Infect Dis 2010; 51:1442-4; PMID:21067353; http://dx.doi.org/10.1086/657429
   PubMed Web of Science ®Google Scholar
• Nair H, Simões EA, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JS, Feikin DR, Mackenzie GA, Moïsi JC, Roca A, Baggett HC, et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet 2013; 381:1380-90; PMID:23369797; http://dx.doi.org/10.1016/S0140-6736(12)61901-1
   PubMed Web of Science ®Google Scholar
• Carrillo-Santisteve P, Ciancio BC, Nicoll A, Lopalco PL. The importance of influenza prevention for public health. Hum Vaccin Immunother 2012; 8:89-95; PMID:22251992; http://dx.doi.org/10.4161/hv.8.1.19066
   PubMed Web of Science ®Google Scholar
• Jit M, Newall AT, Beutels P. Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. Hum Vaccin Immunother 2013; 9:834-40; PMID:23357859; http://dx.doi.org/10.4161/hv.23637
   PubMed Web of Science ®Google Scholar
• de Waure C. Veneziano MA, Cadeddu C, Capizzi S, Specchia ML, Capri S, Ricciardi W. Economic value of influenza vaccination. Hum Vaccin Immunother 2012; 8:119-29; PMID:22251999; http://dx.doi.org/10.4161/hv.8.1.18420
   PubMed Web of Science ®Google Scholar
• Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, Shupo F, Samson SI. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health 2014; 14:813; PMID:25103091; http://dx.doi.org/10.1186/1471-2458-14-813
   PubMed Web of Science ®Google Scholar
• Chiu C, Ellebedy AH, Wrammert J, Ahmed R. B cell responses to influenza infection and vaccination. Curr Top Microbiol Immunol 2014; 386:381-98; Epub ahead of print, Sep 6; PMID:25193634; http://dx.doi.org/10.1007/82_2014_425
   PubMedGoogle Scholar
• Fox A, Mai LQ, Thanh LT, Wolbers M, Le Khanh Hang N, Thai PQ, Thu Yen NT, Minh Hoa LN, Bryant JE, Duong TN, et al. Hemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infection. J Infect 2015; 70:187-96. http://dx.doi.org/10.1016/j.jinf.2014.09.003
   PubMed Web of Science ®Google Scholar
• Babon JA, Cruz J, Orphin L, Pazoles P, Co MD, Ennis FA, Terajima M. Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases. Hum Immunol 2009; 70:711-21; PMID:19524006; http://dx.doi.org/10.1016/j.humimm.2009.06.004
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Kreijtz JH, Bodewes R, Fouchier RA, Osterhaus AD. Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 2009; 27:6363-5; PMID:19840674; http://dx.doi.org/10.1016/j.vaccine.2009.01.016
   PubMed Web of Science ®Google Scholar
• Grant E, Wu C, Chan KF, Eckle S, Bharadwaj M, Zou QM, Kedzierska K, Chen W. Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses. Immunol Cell Biol 2013; 91:184-94; PMID:23399741; http://dx.doi.org/10.1038/icb.2012.78
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274-80; PMID:22286307; http://dx.doi.org/10.1038/nm.2612
   PubMed Web of Science ®Google Scholar
• Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013; 19:1305-12; PMID:24056771; http://dx.doi.org/10.1038/nm.3350
   PubMed Web of Science ®Google Scholar
• Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng N-Y, Nishtala M, Wrammert J, Smith K, James JA, et al. Limited efficacy of inactivated influenza vaccine in the elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest 2014; 121:3109-19; http://dx.doi.org/10.1172/JCI57834
   Web of Science ®Google Scholar
• McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, Hager WD, Barry MB, Kleppinger A, Wang Y, Bleackley RC. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009; 27:2418-25; PMID:19368783; http://dx.doi.org/10.1016/j.vaccine.2009.01.136
   PubMed Web of Science ®Google Scholar
• Hsu JP, Phoon MC, Koh GC, Chen MI, Lee VJ, Wu Y, Xie ML, Cheong A, Leo YS, Chow VT. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers. Int J Infect Dis 2012; 16:e621-7; PMID:22704721; http://dx.doi.org/10.1016/j.ijid.2012.04.010
   PubMedGoogle Scholar
• Dolfi DV, Mansfield DK, Kurupati RK, Kanan S, Doyle SA, Ertl HC, Schmader KE, Wherry EJ. Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans. PLoS One 2013; 8:e77164; PMID:24155927; http://dx.doi.org/10.1371/journal.pone.0077164
   PubMed Web of Science ®Google Scholar
• Miller MS, Palese P. Peering into the crystal ball: influenza pandemics and vaccine efficacy. Cell 2014; 157:294-9; PMID:24725400; http://dx.doi.org/10.1016/j.cell.2014.03.023
   PubMedGoogle Scholar
• Cox RJ. Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother 2013; 9:405-8; PMID:23291930; http://dx.doi.org/10.4161/hv.22908
   PubMed Web of Science ®Google Scholar
• Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Exp Rev Vaccines 2013; 12:519-36; PMID:23659300; http://dx.doi.org/10.1586/erv.13.35
   PubMed Web of Science ®Google Scholar
• Bonduelle O, Carrat F, Luyt CE, Leport C, Mosnier A, Benhabiles N, Krivine A, Rozenberg F, Yahia N, Samri A, et al. Characterization of pandemic influenza immune memory signature after vaccination or infection. J Clin Invest 2014; 124:3129-36; PMID:24911149; http://dx.doi.org/10.1172/JCI74565
   PubMedGoogle Scholar
• He XS, Holmes TH, Mahmood K, Kemble GW, Dekker CL, Arvin AM, Greenberg HB. Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J Infect Dis 2008; 197:803-11; PMID:18279048; http://dx.doi.org/10.1086/528804
   PubMed Web of Science ®Google Scholar
• Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011; 204:845-53; PMID:21846636; http://dx.doi.org/10.1093/infdis/jir436
   PubMed Web of Science ®Google Scholar
• Rudenko L, Kiseleva I, Naykhin AN, Erofeeva M, Stukova M, Donina S, Petukhova G, Pisareva M, Krivitskaya V, Grudinin M, et al. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine. PLoS One 2014; 9:e87962; PMID:24533064; http://dx.doi.org/10.1371/journal.pone.0087962
   PubMed Web of Science ®Google Scholar
• Sasaki S, Holmes TH, Albrecht RA, Garcia-Sastre A, Dekker CL, He XS, Greenberg HB. Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines. J Infect Dis 2014; 210:865-74; PMID:24676204; http://dx.doi.org/10.1093/infdis/jiu190
   PubMed Web of Science ®Google Scholar
• Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158-66; PMID:22551811; http://dx.doi.org/10.1093/infdis/jis330
   PubMed Web of Science ®Google Scholar
• Nayak JL, Fitzgerald TF, Richards KA, Yang H, Treanor JJ, Sant AJ. CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine. J Infect Dis 2013; 207:297-305; PMID:23148285; http://dx.doi.org/10.1093/infdis/jis684
   PubMed Web of Science ®Google Scholar
• Pedersen GK, Madhun AS, Beakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158-66; PMID:22551811; http://dx.doi.org/10.1093/infdis/jis330
   PubMed Web of Science ®Google Scholar
• Edwards EM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169:68-76; PMID:8277200; http://dx.doi.org/10.1093/infdis/169.1.68
   PubMed Web of Science ®Google Scholar
• Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza vaccine. J Infect Dis 2000; 181(3):1133-1137; PMID:10720541; http://dx.doi.org/10.1086/315323
   PubMed Web of Science ®Google Scholar
• Beyer WE, Palache AM, de Jong JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002; 20(9–10):134-153; PMID:11818152; http://dx.doi.org/10.1016/S0264-410X(01)00471-6
   PubMedGoogle Scholar
• Lee MS, Mahmood K, Adhikary L, August JM, Cordova J, Cho I, Kemble G, Reisinger K, Walker RE, Mendelman PM. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr Infect Dis J 2004; 23:852-6; PMID:15361726; http://dx.doi.org/10.1097/01.inf.0000137566.87691.3b
   PubMed Web of Science ®Google Scholar
• Sasaki S, Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW, Arvin AM, Greenberg HB. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza vaccines. J Virol 2007; 81:215-28; PMID:17050593; http://dx.doi.org/10.1128/JVI.01957-06
   PubMed Web of Science ®Google Scholar
• Lu B, Zhou H, Ye D, Kemble G, Jin H. Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics. J Virol 2005; 79:6763-71; PMID:15890915; http://dx.doi.org/10.1128/JVI.79.11.6763-6771.2005
   PubMedGoogle Scholar
• Horimoto T, Takada A, Fujii K, Goto H, Hatta M, Watanabe S, Iwatsuki-Horimoto K, Ito M, Tagawa-Sakai Y, Yamada S, et al. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 2006; 24:3669-76; PMID:16378663; http://dx.doi.org/10.1016/j.vaccine.2005.07.005
   PubMed Web of Science ®Google Scholar
• Donis RO; The Influenza Cell Culture Working Group. Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing. Vaccine 2014; 32(48):6583-90; Epub ahead of print, Jun 24; http://dx.doi.org/10.1016/j.vaccine.2014.06.045
   PubMed Web of Science ®Google Scholar
• Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC. Alternations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985; 143:166-74; PMID:4060580; http://dx.doi.org/10.1016/0042-6822(85)90105-9
   PubMed Web of Science ®Google Scholar
• Katz JM, Naeve CW, Webster RG. Host cell-mediated variation in H3N2 influenza viruses. Virology 1987; 156:386-95; PMID:3811239; http://dx.doi.org/10.1016/0042-6822(87)90418-1
   PubMed Web of Science ®Google Scholar
• Robertson JS, Bootman JS, Newman R, Oxford JS, Daniels RS, Webster RG, Schild GC. Structural changes in the hemagglutinin which accompany egg adaptation of an influenza A (H1N1) virus. Virology 1987; 160:31-7; PMID:3629978; http://dx.doi.org/10.1016/0042-6822(87)90040-7
   PubMed Web of Science ®Google Scholar
• Katz JM, Webster RG. Antigenic and structural characterization of multiple subpopulations of H3N2 influenza virus from an individual. Virology 1988; 165:446-56; PMID:3407150; http://dx.doi.org/10.1016/0042-6822(88)90588-0
   PubMed Web of Science ®Google Scholar
• Wang ML, Katz JM, Webster RG. Extensive heterogeneity in the hemagglutinin of egg-grown influenza viruses from different patients. Virology 1989; 171:275-9; PMID:2741346; http://dx.doi.org/10.1016/0042-6822(89)90538-2
   PubMed Web of Science ®Google Scholar
• Katz JM, Webster RG. Amino acid sequence identity between the HA1 of influenza A (H3N2) viruses grown in mammalian and primary chick kidney cells. J Gen Virol 1992; 73:1159-65; PMID:1588320; http://dx.doi.org/10.1099/0022-1317-73-5-1159
   PubMed Web of Science ®Google Scholar
• Wood JM, Oxford JS, Dunleavy U, Newman RW, Major D, Robertson JS. Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule. Virology 1989; 171:214-21; PMID:2741341; http://dx.doi.org/10.1016/0042-6822(89)90528-X
   PubMed Web of Science ®Google Scholar
• Kodihalli S, Justewicz DM, Gubareva LV, Webster RG. Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. J Virol 1995; 69:4888-97; PMID:7609057
   PubMed Web of Science ®Google Scholar
• Alymova IV, Kodihalli S, Govorkova EA, Fanget B, Gerdil C, Webster RG. Immunogenicity and protective efficacy in mice of influenza B virus vaccines growth in mammalian cells. J Virol 1998; 72:4472-7; PMID:9557744
   PubMed Web of Science ®Google Scholar
• Katz JM, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989; 160:191-8; PMID:2760480; http://dx.doi.org/10.1093/infdis/160.2.191
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Kodihalli S, Alymova IV, Fanget B, Webster RG. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. Dev Biol Stand 1999; 98:39-51; PMID:10494958
   PubMedGoogle Scholar
• Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005; 23:2943-52; PMID:15780743; http://dx.doi.org/10.1016/j.vaccine.2004.08.054
   PubMed Web of Science ®Google Scholar
• Jung EJ, Lee KH, Seong BL. Reverse genetic platform for inactivated and live-attenuated influenza vaccine. Exp Mol Med 2010; 42:116-21; PMID:20054235; http://dx.doi.org/10.3858/emm.2010.42.2.013
   PubMed Web of Science ®Google Scholar
• Katz JM, Wang M, Webster RG. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals identity with mammalian cell-grown virus. J Virol 1990; 64:1808-11; PMID:2319652
   PubMed Web of Science ®Google Scholar
• Robertson JS, Bootman JS, Nicolson C, Major D, Robertson EW, Wood JM. The hemagglutinin of influenza B virus present in clinical material is a single species identical to that of mammalian cell-grown virus. Virology 1990; 179:35-40; PMID:2219728; http://dx.doi.org/10.1016/0042-6822(90)90270-2
   PubMedGoogle Scholar
• Robertson JS, Nicolson C, Bootman JS, Major D, Robertson EW, Wood JM. Sequence analysis of the haemagglutinin (HA) of influenza A (H1N1) viruses present in clinical material and comparison with the HA of laboratory-derived virus. J Gen Virol 1991; 72:2671-77; PMID:1940864; http://dx.doi.org/10.1099/0022-1317-72-11-2671
   PubMedGoogle Scholar
• Govorkova EA, Murti G, Meigneier B, deTaisne C, Webster RG. African green monkey (Vero) cells provide an alternative host cell system for influenza A and B viruses. J Virol 1996; 70:5519-24; PMID:8764064
   PubMed Web of Science ®Google Scholar
• Kishida N, Fujisaki S, Yokoyama M, Sato H, Saito R, Ikematsu H, Xu H, Takashita E, Tashiro M, Takao S, et al. Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs. Clin Vac Immunol 2012; 19:897-908; PMID:22492743; http://dx.doi.org/10.1128/CVI.05726-11
   PubMed Web of Science ®Google Scholar
• Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 2009; 8:607-18; PMID:19397417; http://dx.doi.org/10.1586/erv.09.19
   PubMed Web of Science ®Google Scholar
• Desmyter J, Melnick JL, Rawls WE. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol 1968; 2:955-61; PMID:4302013
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Kaverin NV, Gubareva LV, Meignier B, Webster RG. Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero). J Infect Dis 1995; 172:250-3; PMID:7797924; http://dx.doi.org/10.1093/infdis/172.1.250
   PubMed Web of Science ®Google Scholar
• Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bandixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998; 16:960-8; PMID:9682344; http://dx.doi.org/10.1016/S0264-410X(97)00301-0
   PubMed Web of Science ®Google Scholar
• Zhou F, Zhou J, Ma L, Song S, Zhang X, Li W, Jiang S, Wang Y, Liao G. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1. Biochem Biophys Res Commun 2012; 421:850-4; PMID:22554519; http://dx.doi.org/10.1016/j.bbrc.2012.04.101
   PubMed Web of Science ®Google Scholar
• Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Eder G, Dorner F. Development of a Vero cell-derived influenza whole virus vaccine. Dev Biol Stand 1999; 98:101-10; discussion 111; PMID:10494963
   PubMedGoogle Scholar
• Kistner O, Howard MK, Spruth M, Wodal W, Brühl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M, et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007; 25:6028-36; PMID:17614165; http://dx.doi.org/10.1016/j.vaccine.2007.05.013
   PubMed Web of Science ®Google Scholar
• Whiteley A, Major D, Legastelois I, Campitelli L, Donatelli I, Thompson CI, Zambon MC, Wood JM, Barclay WS. Generation of candidate human influenza vaccine strains in cell culture – rehearsing the European response to an H7N1 pandemic threat. Infl Other Resp Viruses 2007; 1:157-66; PMID:19432631; http://dx.doi.org/10.1111/j.1750-2659.2007.00022.x
   PubMedGoogle Scholar
• Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem 2008; 389:569-77; PMID:18953724; http://dx.doi.org/10.1515/BC.2008.060
   PubMed Web of Science ®Google Scholar
• Kistner O, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, Sabarth N, Falkner FG, Mayerhofer I, Mundt W, Reiter M, et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 2010; 5:e9349; PMID:20186321; http://dx.doi.org/10.1371/journal.pone.0009349
   PubMed Web of Science ®Google Scholar
• Bruhl P, Kerschbaum A, Kistner O, Barrett N, Dorner F, Gerencer M. Humoral and cell-mediated immunity to Vero cell-derived influenza vaccine. Vaccine 2000; 19:1149-58; PMID:11137251; http://dx.doi.org/10.1016/S0264-410X(00)00316-9
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:2573-84; PMID:18550874; http://dx.doi.org/10.1056/NEJMoa073121
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Muller M, Fritsch S, Zeitlinger M, Berezuk G, Loew-Baselli A, van der Velden MV, Pollabauer EM, Maritsch F, Pavlova BG, et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009; 200:1113-8; PMID:19712040; http://dx.doi.org/10.1086/605608
   PubMed Web of Science ®Google Scholar
• Keitel WA, Keitel WA, Dekker CL, Mink C, Campbell JD, Edwards KM, Patel SM, Ho DY, Talbot HK, Guo K, et al. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine 2009; 27:6642-8; PMID:19773098; http://dx.doi.org/10.1016/j.vaccine.2009.03.015
   PubMed Web of Science ®Google Scholar
• Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, et al. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 2012; 30:329-35; PMID:22080174; http://dx.doi.org/10.1016/j.vaccine.2011.10.088
   PubMed Web of Science ®Google Scholar
• van der Velden MV, Aichinger G, Pollabauer EM, Loew-Baselli A, Fritsch S, Benamara K, Kistner O, Muller M, Zeitlinger M, Kollaritsch H, et al. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine 2012; 30:6127-35; PMID:22884662; http://dx.doi.org/10.1016/j.vaccine.2012.07.077
   PubMed Web of Science ®Google Scholar
• van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, et al. Safety and immunogenicity of a Vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population. J Infect Dis 2014; 209:12-23; PMID:24041789; http://dx.doi.org/10.1093/infdis/jit498
   PubMed Web of Science ®Google Scholar
• Fritz R, Sabarth N, Kiermayr S, Hohenadl C, Howard MK, Ilk R, Kistner O, Ehrlich HJ, Barrett PN, Kreil TR. A Vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J Infect Dis 2012; 205:28-34; PMID:22090447; http://dx.doi.org/10.1093/infdis/jir711
   PubMed Web of Science ®Google Scholar
• Crowe BA, Bruhl P, Gerencer M, Schwendinger MG, Pilz A, Kistner O, Koelling-Schlebusch K, Aichinger G, Singer J, Zeitlinger M, et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 2010; 29:166-73; PMID:21055500; http://dx.doi.org/10.1016/j.vaccine.2010.10.065
   PubMed Web of Science ®Google Scholar
• Howard MK, Sabarth N, Savidis-Dacho H, Portsmouth D, Kistner O, Kreil TR, Ehrlich HJ, Barrett PN. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One 2011; 6:e23791; PMID:21876771; http://dx.doi.org/10.1371/journal.pone.0023791
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Berezuk G, Fritsch S, Aichinger G, Singer J, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN. Clinical development of a Vero cell culture-derived seasonal influenza vaccine. Vaccine 2012; 30:4377-86; PMID:22172502; http://dx.doi.org/10.1016/j.vaccine.2011.11.114
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Muller M, Kollaritsh H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, et al. Pre-vaccination immunity an immune responses to a cell culture-derived whole-virus H1N1 vaccine and similar to a seasonal influenza vaccine. Vaccine 2012; 30:4543-51; PMID:22475864; http://dx.doi.org/10.1016/j.vaccine.2012.03.061
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Portsmouth D, Kistner O, Barrett PN. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis 2012; 54:946-54; PMID:22267715; http://dx.doi.org/10.1093/cid/cir959
   PubMed Web of Science ®Google Scholar
• Loew-Baselli A, Pavlova BG, Fritsch S, Poellabauer EM, Draxler W, Kistner O, Behre U, Angemayr R, Neugebauer J, Kirsten K, et al. A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory. Vaccine 2012; 30:5956-66; PMID:22846396; http://dx.doi.org/10.1016/j.vaccine.2012.07.039
   PubMed Web of Science ®Google Scholar
• Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649; PMID:20508026; http://dx.doi.org/10.1136/bmj.c2649
   PubMed Web of Science ®Google Scholar
• Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O, Ehrlich HJ. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011; 377:751-9; PMID:21329971; http://dx.doi.org/10.1016/S0140-6736(10)62228-3
   PubMed Web of Science ®Google Scholar
• Frank AL, Couch RB, Griffis CA, Baxter BD. Comparison of different tissue cultures for isolation and quantitation of influenza and parainfluenza viruses. J Clin Microbiol 1979; 10:32-6; PMID:227920
   PubMed Web of Science ®Google Scholar
• Schepetuik SK, Kok T. The use of MDCK, MEK, and LLCMK2 cell lines with enzyme immunoassay for the isolation of influenza and parainfluenza viruses from clinical specimens. J Virol Methods 1993; 42:241-50; PMID:8390473; http://dx.doi.org/10.1016/0166-0934(93)90036-Q
   PubMedGoogle Scholar
• Reina J, Fernandez-Baca V, Blanco I, Munar M. Comparison of Madin-Darby canine kidney cells (MDCK) with a green monkey continuous cell line (Vero) and human lung embryonated cells (MRC-5) in the isolation of influenza A virus from nasopharyngeal aspirates by shell vial culture. J Clin Microbiol 1997; 35:1900-1; PMID:9196221
   PubMed Web of Science ®Google Scholar
• Romanova J, Katinger D, Ferko B, Voglauer R, Mochalova L, Bovin N, Lim W, Katinger H, Egorov A. Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology 2003; 307:90-7; PMID:12667817; http://dx.doi.org/10.1016/S0042-6822(02)00064-8
   PubMed Web of Science ®Google Scholar
• Seitz C, Frensing T, Höper D, Kochs G, Reichl U. High yields of influenza A virus in Madin-Darby canine kidney cells are promoted by an insufficient interferon-induced antiviral state. J Gen Virol 2010; 91:1754-63; PMID:20357039; http://dx.doi.org/10.1099/vir.0.020370-0
   PubMed Web of Science ®Google Scholar
• Frensing T, Seitz C, Heynisch B, Patzina C, Kochs G, Reichl U. Efficient influenza B virus propagation due to deficient interferon-induced antiviral activity in MDCK cells. Vaccine 2011; 29:7125-9; PMID:21651940; http://dx.doi.org/10.1016/j.vaccine.2011.05.069
   PubMedGoogle Scholar
• Seitz C, Isken B, Heynisch B, Rettkowski M, Frensing T, Reichl U. Trypsin promotes efficient influenza vaccine production in MDCK cells by interfering with the antiviral host response. Appl Microbiol Biotechnol 2012; 93:601-11; PMID:21915610; http://dx.doi.org/10.1007/s00253-011-3569-8
   PubMedGoogle Scholar
• Liu J, Shi X, Schwartz R, Kemble G. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine 2009; 27:6460-3; PMID:19559113; http://dx.doi.org/10.1016/j.vaccine.2009.06.024
   PubMed Web of Science ®Google Scholar
• Hussain AI, Cordeiro M, Sevilla E, Liu J. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 2010; 28:3848-55; PMID:20307595; http://dx.doi.org/10.1016/j.vaccine.2010.03.005
   PubMed Web of Science ®Google Scholar
• van Wielink R, Kant-Eenbergen HC, Harmsen MM, Martens DE, Wijffels RH, Coco-Martin JM. Adaptation of a Madin-Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines. J Virol Methods 2011; 171:53-60; PMID:20933017; http://dx.doi.org/10.1016/j.jviromet.2010.09.029
   PubMed Web of Science ®Google Scholar
• Zhai W, Zhang DN, Mai C, Choy J, Jian G, Sra K, Galinski MS. Comparison of different cell substrates on the measurement of human influenza virus neutralizing antibodies. PLoS One 2012; 7:e52327; PMID:23284988; http://dx.doi.org/10.1371/journal.pone.0052327
   PubMedGoogle Scholar
• Merten OW, Hannoun C, Manuguerra JC, Ventre F, Petres S. Production of influenza virus in cell cultures for vaccine preparation. Adv Exp Med Biol 1996; 397:141-51; PMID:8718593; http://dx.doi.org/10.1007/978-1-4899-1382-1_19
   PubMedGoogle Scholar
• Genzel Y, Dietzsch C, Rapp E, Schwarzer J, Reichl U. MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation. Appl Microbiol Biotechnol 2010; 88:461-75; PMID:20617311; http://dx.doi.org/10.1007/s00253-010-2742-9
   PubMed Web of Science ®Google Scholar
• Youil R, Su Q, Toner TJ, Szymkowiak C, Kwan WS, Rubin B, Petrukhin L, Kiseleva I. Shaw AR, DiStefano D. Comparative study of influenza virus replication in Vero and MDCK cell lines. J Virol Methods 2004; 120:23-31; PMID:15234806; http://dx.doi.org/10.1016/j.jviromet.2004.03.011
   PubMed Web of Science ®Google Scholar
• Makizumi K, Kimachi K, Fukada K, Nishimura T, Kudo Y, Goto S, Odagiri T, Tahiro M, Kino Y. Timely production of A/Fujian-like influenza vaccine matching the 2003-2004 epidemic strain may have been possible using Madin-Darby canine kidney cells. Vaccine 2008; 26:6852-58; PMID:19149013; http://dx.doi.org/10.1016/j.vaccine.2008.09.075
   PubMed Web of Science ®Google Scholar
• Nishiyama K, Sgawara K, Nouchi T, Kawano N, Soejima K, Abe S, Mizokami H. Purification and cDNA cloning of a novel protease inhibitor secreted into culture supernatant by MDCK cells. Biologics 2008; 36:122-33; PMID:17892946; http://dx.doi.org/10.1016/j.biologicals.2007.07.004
   PubMedGoogle Scholar
• Polymenidou M, Trusheim H, Stallmach L, Moos R, Julius C, Miele G, Lenz-Bauer C, Aguzzi A. Canine MDCK cell lines are refractory to infection with human and mouse prions. Vaccine 26:2601-14; PMID:18423803; http://dx.doi.org/10.1016/j.vaccine.2008.03.035
   PubMed Web of Science ®Google Scholar
• Wanich N, Bencharitiwong R, Tsai T, Nowak-Wegrzyn A. In vitro assessment of the allergenicity of a novel influenza vaccine produced in dog kidney cells in individuals with dog allergy. Ann Allergy Asthma Immunol 2010; 104:426-33; PMID:20486334; http://dx.doi.org/10.1016/j.anai.2010.03.012
   PubMed Web of Science ®Google Scholar
• Bencharitiwong R, Leonard S, Tsai T, Nowak-Węgrzyn A. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells. Hum Vaccin Immunother 2012; 8:863-5; PMID:22777093; http://dx.doi.org/10.4161/hv.20324
   PubMed Web of Science ®Google Scholar
• Merten OW, Manuguerra JC, Hannoun C, van der Werf S. Production of influenza virus in serum-free mammalian cell cultures. Dev Biol Stand 1999; 98:23-37; PMID:10494957
   PubMedGoogle Scholar
• Voeten JT, Claas EC, Brands R, Palache AM, van Scharrenburg GJ, Rimmelzwaan GF, Osterhaus AD. Generation and characterization of reassortant influenza A viruses propagated in serum-free cultured MDCK-SF1 cells. Dev Biol Stand 1999; 98:77-87; PMID:10494961
   PubMedGoogle Scholar
• Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 2001; 19:3444-50; PMID:11348709; http://dx.doi.org/10.1016/S0264-410X(01)00053-6
   PubMed Web of Science ®Google Scholar
• Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines 2009; 8:1681-92; PMID:19943763; http://dx.doi.org/10.1586/erv.09.128
   PubMed Web of Science ®Google Scholar
• Genzel Y, Vogel T, Buck J, Behrendt I, Ramirez DV, Schiedner G, Jordan I, Reichl U. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells. Vaccine 2014; 32:2770-81; PMID:24583003; http://dx.doi.org/10.1016/j.vaccine.2014.02.016
   PubMed Web of Science ®Google Scholar
• George M, Farooq M, Dang T, Cortes B, Liu J, Maranga L. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process. Biotechnol Bioeng 2010; 106:906-17; PMID:20589670; http://dx.doi.org/10.1002/bit.22753
   PubMed Web of Science ®Google Scholar
• Sun B, Yu X, Kong W, Sun S, Yang P, Zhu C, Zhang H, Wu Y, Chen Y, Shi Y, et al. Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor. Appl Microbiol Biotechnol 2013; 97:1063-70; PMID:22945265; http://dx.doi.org/10.1007/s00253-012-4375-7
   PubMed Web of Science ®Google Scholar
• Tapia F, Vogel T, Genzel Y, Behrendt I, Hirschel M, Gangemi JD, Reichl U. Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor. Vaccine 2014; 32:1003-11; PMID:24269322; http://dx.doi.org/10.1016/j.vaccine.2013.11.044
   PubMed Web of Science ®Google Scholar
• Lohr V, Genzel Y, Behrendt I, Scharfenberg K, Reichl U. A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor. Vaccine 2010; 28:6256-64; PMID:20638458; http://dx.doi.org/10.1016/j.vaccine.2010.07.004
   PubMed Web of Science ®Google Scholar
• Vlecken DH, Plegrim RP, Ruminski S, Bakker WA, van der Pol LA. Comparison of initial feasibility of host cell lines for viral vaccine production. J Virol Methods 2013; 193:28-41; PMID:23684847; http://dx.doi.org/10.1016/j.jviromet.2013.04.020
   PubMed Web of Science ®Google Scholar
• Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 1997; 176:S20-S23; PMID:9240689; http://dx.doi.org/10.1086/514169
   PubMed Web of Science ®Google Scholar
• Halperin SA, Nestruck AC, Eastwood BJ. Safety and immunogenicity of a new influenza vaccine growth in mammalian cell culture. Vaccine 1998; 16:1331-5; PMID:9682398; http://dx.doi.org/10.1016/S0264-410X(98)00011-5
   PubMed Web of Science ®Google Scholar
• Percheson PB, Trepanier P, Dugre R, Mabrouk T. A Phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line. Dev Biol Stand 1999; 98:127-132; PMID:10494965
   PubMedGoogle Scholar
• Halperin SA, Smith B, Mabrouk T, Germain M, Trepanier P, Hassell T, Treanor J, Gauthier R, Mills EL. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002; 20:1240-7; PMID:11803087; http://dx.doi.org/10.1016/S0264-410X(01)00428-5
   PubMed Web of Science ®Google Scholar
• Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine 2009; 27:6022-9; PMID:19666152; http://dx.doi.org/10.1016/j.vaccine.2009.07.083
   PubMed Web of Science ®Google Scholar
• Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 2009; 27:786-91; PMID:19027046; http://dx.doi.org/10.1016/j.vaccine.2008.11.003
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009; 200:849-57; PMID:19673652; http://dx.doi.org/10.1086/605506
   PubMed Web of Science ®Google Scholar
• Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009; 200:841-8; PMID:19673651; http://dx.doi.org/10.1086/605505
   PubMed Web of Science ®Google Scholar
• Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997-1004; PMID:20868284; http://dx.doi.org/10.1086/656578
   PubMed Web of Science ®Google Scholar
• Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr Infect Dis J 2012; 31:494-500; PMID:22301476; http://dx.doi.org/10.1097/INF.0b013e31824bb179
   PubMed Web of Science ®Google Scholar
• Oxford JS, Al-Jabri AA, Lambkin R, Palache AM, Fleming DM. Non-responders to egg grown influenza vaccine seroconvert after booster immunization with MDCK cell grown vaccine. Vaccine 2003; 21:2743-6; PMID:12798612; http://dx.doi.org/10.1016/S0264-410X(03)00214-7
   PubMed Web of Science ®Google Scholar
• Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuvanagi H, Kusadokoro H, Sawata H, et al. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Vaccine 2012; 30:5030-7; PMID:22472791; http://dx.doi.org/10.1016/j.vaccine.2012.03.053
   PubMed Web of Science ®Google Scholar
• Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. Vaccine 2012; 30:4820-7; PMID:22626675; http://dx.doi.org/10.1016/j.vaccine.2012.05.013
   PubMed Web of Science ®Google Scholar
• Reynales H, Astudillo P, de Valliere S, Hatz C, Schlagenhauf P, Rath B, Velentgas P, Farina A, Sales-Carmona V, Groth N. A prospective observational safety study on MF59® adjuvanted cell culture-derived vaccine, Celtura® during the A/H1N1 (2009) influenza pandemic. Vaccine 2012; 30:6436-43; PMID:22902681; http://dx.doi.org/10.1016/j.vaccine.2012.08.005
   PubMed Web of Science ®Google Scholar
• Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Thee⇓ W, Burchard GD, Cramer JP. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study. Hum Vaccin Immunother 2014; 10:441-8; PMID:24240428; http://dx.doi.org/10.4161/hv.27140
   PubMed Web of Science ®Google Scholar
• Pan SC, Kung HC, Kao TM, Wu H, Dong SX, Hu MH, Chou AH, Chong P, Hsieh SM, Chang SC. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan. J Microbiol Immunol Infect 2013; 46:448-55; PMID:23022464; http://dx.doi.org/10.1016/j.jmii.2012.08.002
   PubMedGoogle Scholar
• Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. 2009. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine – preliminary report. New Engl J Med 2009; 361:2424-35; PMID:19745215; http://dx.doi.org/10.1056/NEJMoa0907650
   PubMed Web of Science ®Google Scholar
• Loebermann M, Voss U, Meyer S, Bosse D, Fritzche C, Klammt S, Frimmel S, Riebold D, Reisinger EC. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination. PLoS One 2013; 8:e70866; PMID:23976960; http://dx.doi.org/10.1371/journal.pone.0070866
   PubMedGoogle Scholar
• Basavaraj VH, Sampath G, Hegde NR, Mohan VK, Ella KM. Evaluation of safety and immunogenicity of HNVAC, an MDCK-based H1N1 pandemic influenza vaccine, in Phase I single centre and Phase II/III multi-centre, double-blind, randomized, placebo-controlled, parallel assignment studies. Vaccine 2014; 32:4592-7; PMID:24856782; http://dx.doi.org/10.1016/j.vaccine.2014.05.039
   PubMed Web of Science ®Google Scholar
• Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Sawata H, Nakura N, Jaeger RK, Lattanzi M. Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children. Adv Ther 2010; 27:444-57; PMID:20586002; http://dx.doi.org/10.1007/s12325-010-0043-4
   PubMedGoogle Scholar
• Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G. A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Vaccine 2012; 30:3470-7; PMID:22446638; http://dx.doi.org/10.1016/j.vaccine.2012.03.017
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Holmes SJ, Pedotti P, Arora AK, Lattanzi M. A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination. Hum Vaccin Immunother 2014; 10:(8):2395-407; [Epub ahead of print]; PMID:25424947; http://dx.doi.org/10.4161/hv.29393
   PubMed Web of Science ®Google Scholar
• Heldens J, Hulskotte E, Voeten T, Breedveld B, Verwey P, van Duijnhoven W, Rudenko L, van Damme P, van den Bosch H. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers. Vaccine 2014; 32:5118-24; PMID:24858566; http://dx.doi.org/10.1016/j.vaccine.2014.05.030
   PubMed Web of Science ®Google Scholar
• Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998; 9:1909-17; PMID:9741429; http://dx.doi.org/10.1089/hum.1998.9.13-1909
   PubMed Web of Science ®Google Scholar
• Lewis JA, Brown EL, Duncan PA. Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev Biol (Basel) 2006; 123:165-76; discussion 183-97; PMID:16566444
   PubMedGoogle Scholar
• Koudstaal W, Hartgroves L, Havenga M, Legastelois I, Ophorst C, Sieuwerts M, Zuijdgeest D, Vogels R, Custers J, de Boer-Luijtze E, et al. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine 2009; 27:2588-93; PMID:19428865; http://dx.doi.org/10.1016/j.vaccine.2009.02.033
   PubMed Web of Science ®Google Scholar
• Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001; 19:2716-21; PMID:11257414; http://dx.doi.org/10.1016/S0264-410X(00)00508-9
   PubMed Web of Science ®Google Scholar
• Hartgroves LC, Koudstaal W, McLeod C, Moncorgé O, Thompson CI, Ellis J, Bull C, Havenga MJ, Goudsmit J, Barclay WS. Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. Vaccine 2010; 28:2973-9; PMID:20188682; http://dx.doi.org/10.1016/j.vaccine.2010.02.012
   PubMedGoogle Scholar
• Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M, Vogel FR, Barclay W, et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009; 27:1889-97; PMID:19368768; http://dx.doi.org/10.1016/j.vaccine.2009.01.116
   PubMed Web of Science ®Google Scholar
• Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36:59-74; PMID:886304; http://dx.doi.org/10.1099/0022-1317-36-1-59
   PubMed Web of Science ®Google Scholar
• Le Ru A, Jacob D, Transfiguracion J, Ansorge S, Henry O, Kamen AA. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine 2010; 28: 3661-71; PMID:20347632; http://dx.doi.org/10.1016/j.vaccine.2010.03.029
   PubMed Web of Science ®Google Scholar
• Lohr V, Genzel Y, Jordan I, Katinger D, Mahr S, Sandig V, Reichl U. Live attenuated influenza viruses produced in suspension process with avail AGE1.CR.pIX cells. BMC Biotechnol 2012; 12:79; PMID:23110398; http://dx.doi.org/10.1186/1472-6750-12-79
   PubMedGoogle Scholar
• Jordan I, Vos A, Beilfuss S, Neubert A, Breul S, Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine 2009; 27:748-56; PMID:19071186; http://dx.doi.org/10.1016/j.vaccine.2008.11.066
   PubMed Web of Science ®Google Scholar
• Lohr V, Hadicke O, Genzel Y, Jordan I, Buntemeyer H, Klamt S, Reichl U. The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis. BMC Biotechnol 2014; 14:72; PMID:25077436; http://dx.doi.org/10.1186/1472-6750-14-72
   PubMedGoogle Scholar
• Brown SW, Mehtali M. The avian EB66R cell line, application to vaccines, and therapeutic protein production. PDA J Pharm Sci Technol 2010; 64:419-25; PMID:21502045
   PubMedGoogle Scholar
• Smith KA, Colvin CJ, Weber PS, Spatz SJ, Coussens PM. High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases. Vaccine 2008; 26:3778-82; PMID:18524432; http://dx.doi.org/10.1016/j.vaccine.2008.04.048
   PubMed Web of Science ®Google Scholar
• Coussens PM, Smith KA, Weber PS, Colvin CJ. Immortalized chick embryo cell line adapted to serum-free growth conditions and capable of replicating human and reassortant H5N1 influenza strains for vaccine production. Vaccine 2011; 29:8661-8; PMID:21911025; http://dx.doi.org/10.1016/j.vaccine.2011.08.122
   PubMed Web of Science ®Google Scholar
• Schultz-Cherry S, Dybdahl-Sissoko N, McGregor M, Hinshaw VS. Mink lung epithelial cells: unique cell line that supports influenza A and B virus replication. J Clin Microbiol 1998; 36:3718-20; PMID:9817906
   PubMed Web of Science ®Google Scholar
• Huang YT, Turchek BM. Mink lung cells and mixed mink lung and A549 cells for rapid detection of influenza virus and other respiratory viruses. J Clin Microbiol 2000; 38:422-3; PMID:10618131
   PubMed Web of Science ®Google Scholar
• Hamilton SB, Wyatt DE, Wahlgren BT, O'Dowd MK, Morrissey JM, Daniels DE, Lednicky JA. Higher titers of some H5N1 and recent human H1N1 and H3N2 influenza viruses in Mv1 Lu vs. MDCK cells. Virol J 2011; 8:66; PMID:21314955; http://dx.doi.org/10.1186/1743-422X-8-66
   PubMed Web of Science ®Google Scholar
• Nakamura K, Homma M. Protein synthesis in Vero cells abortively infected with influenza B virus. J Gen Virol 1981; 56:199-202; PMID:7299373; http://dx.doi.org/10.1099/0022-1317-56-1-199
   PubMed Web of Science ®Google Scholar
• Lau SC, Scholtissek C. Abortive infection of Vero cells by an influenza A virus (FPV). Virology 1995; 212:225-31; PMID:7676635; http://dx.doi.org/10.1006/viro.1995.1473
   PubMed Web of Science ®Google Scholar
• Kaverin NV, Webster RG. Impairment of multicycle influenza virus growth in Vero (WHO) cells by loss of trypsin activity. J Virol 1995; 69:2700-3; PMID:7884927
   PubMed Web of Science ®Google Scholar
• Roedig JV, Rapp E, Hoper D, Genzel Y, Reichl U. Impact of host cell line adaptation on quasispecies composition and glycosylation of influenza A virus hemagglutinin. PLoS One 2011; 6:e27989; PMID:22163276; http://dx.doi.org/10.1371/journal.pone.0027989
   PubMed Web of Science ®Google Scholar
• Tseng YF, Hu AY, Huang ML, Yeh WZ, Weng TC, Chen YS, Chong P, Lee MS. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness. PLoS One 2011; 6:e24057; PMID:22022351; http://dx.doi.org/10.1371/journal.pone.0024057
   PubMed Web of Science ®Google Scholar
• Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, García-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 1999; 73:9679-82; PMID:10516084
   PubMed Web of Science ®Google Scholar
• Ozaki H, Govorkova EA, Li C, Xiong X, Webster RG, Webby RJ. Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. J Virol 2004; 78:1851-7; PMID:14747549; http://dx.doi.org/10.1128/JVI.78.4.1851-1857.2004
   PubMed Web of Science ®Google Scholar
• Krause PR. Use of MDCK Cells for Manufacture of Inactivated Influenza Vaccines: Introduction. Vaccines and Related Biological Products Advisory Committee, Center for Biologics Evaluation and Research, Taylor & Francis. 2005; www.fda.gov/ohrms/dockets/ac/05/slides/5-4188S1-1draft.PPT
   Google Scholar
• Groner A, Vorlop J (inventors); Novartis Vaccines and Diagnostics, Inc., (assignee). Animal cells and processes for the replication of influenza viruses. 1997. Patent No. WO/1997/037000.
   Google Scholar
• Liu J, Mani S, Schwartz R, Richman L, Tabor DE. Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine 2010; 28:1285-93; PMID:19944150; http://dx.doi.org/10.1016/j.vaccine.2009.11.023
   PubMed Web of Science ®Google Scholar
• Omeir RL, Teferedegne B, Foseh GS, Beren JJ, Snoy PJ, Brinster LR, Cook JL, Peden K, Lewis AM Jr. Heterogeneity of the tumorigenic phenotype expressed by Madin-Darby canine kidney cells. Comp Med 2011; 61:243-50; PMID:21819694
   PubMed Web of Science ®Google Scholar
• Vepachedu RS, Menon A, Hussain AI, Liu J. Evaluation of tumorigenic potential of high yielding cloned MDCK cells for live-attenuated influenza vaccine using in vitro growth characteristics, metastatic gene expression and in vivo nude mice model. Biologicals 2012; 40:482-94; PMID:22902973; http://dx.doi.org/10.1016/j.biologicals.2012.06.005
   PubMedGoogle Scholar
• Madin-Darby canine kidney continuous cell line. Briefing document, Solvay Pharmaceuticals, Vaccines and Related Biologicals Advisory Committee (VRBPAC), Center for Biologics Evaluation and Research, Taylor & Francis. 2005; http://www.fda.gov/ohrms/dockets/ac/05/briefing/5-4188b1_19a.pdf
   Google Scholar
• Use of Madin Darby canine kidney cells for the manufacture of live, attenuated influenza vaccines. Briefing document, MedImmune, Vaccines and Related Biologicals Advisory Committee (VRBPAC), Center for Biologics Evaluation and Research, Taylor & Francis. 2008; http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4384B1_4.pdf
   Google Scholar
• Onions D, Egan W, Jarrett R, Novicki D, Gregersen JP. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 2010; 38:544-51; PMID:20537553; http://dx.doi.org/10.1016/j.biologicals.2010.04.003
   PubMed Web of Science ®Google Scholar
• Hegde NR, Kumar D, Rao PP, Kumari PK, Kaushik Y, Ravikrishnan R, Prasad SD, Ella KM. Development and preclinical testing of HNVAC, a cell culture-based H1N1 pandemic influenza vaccine from India. Vaccine 2014; 32:3636-43; PMID:24801052; http://dx.doi.org/10.1016/j.vaccine.2014.04.072
   PubMedGoogle Scholar
• Lewis AM Jr, Krause P, Peden K. A defined-risk approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture. Dev Biol 2001; 106:513-35; PMID:11761266
   PubMedGoogle Scholar
• Medema JK, Meijer J, Kersten AJ, Horton R. Safety assessment of Madin Darby canine kidney cells as vaccine substrate. Dev Biol 2006; 123:243-50; PMID:16566450
   PubMedGoogle Scholar
• Gregersen JP. A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines. Vaccine 2008; 26:3297-304; PMID:18468737; http://dx.doi.org/10.1016/j.vaccine.2008.03.076
   PubMed Web of Science ®Google Scholar
• Gregersen JP. A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine 2008; 26:3332-40;PMID:18485545; http://dx.doi.org/10.1016/j.vaccine.2008.03.075
   PubMed Web of Science ®Google Scholar
• Murata H, Macauley J, Lewis AM Jr, Peden K. Plaque purification as a method to mitigate the risk of adventitious-agent contamination in influenza vaccine virus seeds. Vaccine 2011; 29:3155-61; PMID:21354480; http://dx.doi.org/10.1016/j.vaccine.2011.02.041
   PubMedGoogle Scholar
• Hess RD, Weber F, Watson K, Schmitt S. Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines. Vaccine 2012; 30:2715-27; PMID:22342707; http://dx.doi.org/10.1016/j.vaccine.2012.02.015
   PubMed Web of Science ®Google Scholar
• Roth B, Mohr H, Enders M, Garten W, Gregersen JP. Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses. Vaccine 2012; 30:517-22; PMID:22119922; http://dx.doi.org/10.1016/j.vaccine.2011.11.063
   PubMed Web of Science ®Google Scholar
• Ledwith BJ, Lanning CL, Gumprecht LA, Anderson CA, Coleman JB, Gatto NT, Balasubramanian G, Farris GM, Kemp RK, Harper LB, et al. Tumorigenicity assessments of Per.ER C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line. Dev Biol 2006; 123:251-63; discussion 265; PMID:16566451
   PubMedGoogle Scholar
• Robertson JS, Cook P, Attwell AM, Williams SP. Replicative advantage in tissue culture of egg-adapted influenza virus over tissue culture-derived virus: implications for vaccine manufacture. Vaccine 1995; 13:1583-8; PMID:8578846; http://dx.doi.org/10.1016/0264-410X(95)00085-F
   PubMed Web of Science ®Google Scholar
• Lin YP, Wharton SA, Martin J, Skehel JJ, Wiley DC, Steinhauer DA. Adaptation of egg-grown and transfectant influenza viruses for growth in mammalian cells: selection of hemagglutinin mutants with elevated pH of membrane fusion. Virology 1997; 233:402-10; PMID:9217063; http://dx.doi.org/10.1006/viro.1997.8626
   PubMedGoogle Scholar
• Lee HK, Tang JW, Kong DH, Loh TP, Chiang DK, Lam TT, Koay ES. Comparison of mutation patterns in full-genome A/H3N2 influenza sequences obtained directly from clinical samples and the same samples after a single MDCK passage. PLoS One 2013; 8:e79252; PMID:24223916; http://dx.doi.org/10.1371/journal.pone.0079252
   PubMed Web of Science ®Google Scholar
• Opitz L, Zimmermann A, Lehmann S, Genzel Y, Lübben H, Reichl U, Wolff MW. Capture of cell culture-derived influenza virus by lectins: strain independent, but host cell dependent. J Virol Methods 2008; 154:61-8; PMID:18840469; http://dx.doi.org/10.1016/j.jviromet.2008.09.004
   PubMedGoogle Scholar
• Hutter J, Rodig JV, Hoper D, Seeberger PH, Reichl U, Rapp E, Lepenies B. Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity. J Immunol 2013; 190:220-30; PMID:23225881; http://dx.doi.org/10.4049/jimmunol.1201060
   PubMed Web of Science ®Google Scholar